---
schema_version: "secwatch.filing_event.v1"
accession: "0001792044-22-000026"
form_type: "8-K"
ticker: "VTRS"
cik: "0001792044"
company_name: "Viatris Inc"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:58:22.097760+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viatris Q2 2022: Revenue $4.12B, adj. EBITDA $1.48B, reaffirms guidance

## Summary
- Total revenues $4.12B; U.S. GAAP net earnings $314M; adjusted EBITDA $1.48B.
- Free cash flow $719M in Q2; H1 free cash flow ~$1.8B.
- Reaffirms adjusted EBITDA and free cash flow guidance; revises total revenue guidance for FX.
- Declares quarterly dividend $0.12 per share; paid down ~$1.5B debt in H1, on track for $2B full year.
- Biocon Biologics transaction on track for H2 2022 close.

## SEC filing metadata
- accession: 0001792044-22-000026
- form_type: 8-K
- ticker: VTRS
- cik: 0001792044
- company_name: Viatris Inc
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792044/000179204422000026/0001792044-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792044/000179204422000026/vtrs-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001792044-22-000026
- JSON: https://secwatch.observer/filing/0001792044-22-000026.json
- Plain text: https://secwatch.observer/filing/0001792044-22-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.